Discovery of a Small Molecule Tat-trans-Activation-responsive RNA Antagonist That Potently Inhibits Human Immunodeficiency Virus-1 Replication*
暂无分享,去创建一个
Hong Cao | Akbar Ali | Yueh-Hsin Ping | Kuan-Teh Jeang | Tariq M Rana | T. Rana | K. Jeang | Y. Ping | Akbar Ali | H. Cao | K. Kibler | Seongwoo Hwang | Karen Kibler | Natarajan Tamilarasu | Seongwoo Hwang | N. Tamilarasu
[1] T. Rana,et al. Controlling human immunodeficiency virus type 1 gene expression by unnatural peptides. , 1999, Biochemistry.
[2] Kuan-Teh Jeang,et al. Tat and Trans-activation-responsive (TAR) RNA-independent Induction of HIV-1 Long Terminal Repeat by Human and Murine Cyclin T1 Requires Sp1* , 2003, The Journal of Biological Chemistry.
[3] W. Wilson,et al. Design and analysis of molecular motifs for specific recognition of RNA. , 1997, Bioorganic & medicinal chemistry.
[4] M. Wigler,et al. Complex synthetic chemical libraries indexed with molecular tags. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[5] Stephen B. H. Kent,et al. Efficient method for the preparation of peptoids [oligo(N-substituted glycines)] by submonomer solid-phase synthesis , 1992 .
[6] J A Grobler,et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. , 2000, Science.
[7] A. Rice,et al. Specific interaction of the human immunodeficiency virus Tat proteins with a cellular protein kinase. , 1993, Virology.
[8] I. Tinoco,et al. Structural Elements in RNA , 1991, Progress in Nucleic Acid Research and Molecular Biology.
[9] W. C. Still,et al. Inhibition of gene expression in human cells through small molecule-RNA interactions. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[10] B. Cullen,et al. Recruitment of cyclin T1/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[11] M. Garber,et al. HIV-1 TAR RNA Enhances the Interaction between Tat and Cyclin T1* , 2000, The Journal of Biological Chemistry.
[12] M. Malim,et al. HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. , 1998, Science.
[13] A. Rice,et al. Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor , 1995, Journal of virology.
[14] A. Srinivasan,et al. Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis. , 1989, Nucleic acids research.
[15] Christine S. Chow,et al. A Structural Basis for RNA−Ligand Interactions , 1997 .
[16] M. Eisenstein,et al. Neomycin B-arginine conjugate, a novel HIV-1 Tat antagonist: synthesis and anti-HIV activities. , 2001, Biochemistry.
[17] D. Capon,et al. A discrete element 3' of human immunodeficiency virus 1 (HIV-1) and HIV-2 mRNA initiation sites mediates transcriptional activation by an HIV trans activator , 1988, Molecular and cellular biology.
[18] T. Rana,et al. DSIF and NELF Interact with RNA Polymerase II Elongation Complex and HIV-1 Tat Stimulates P-TEFb-mediated Phosphorylation of RNA Polymerase II and DSIF during Transcription Elongation* , 2001, The Journal of Biological Chemistry.
[19] E Westhof,et al. RNA as a drug target: chemical, modelling, and evolutionary tools. , 1998, Current opinion in biotechnology.
[20] K. Jones,et al. Taking a new TAK on tat transactivation. , 1997, Genes & development.
[21] B. Peterlin,et al. Tat transactivation: a model for the regulation of eukaryotic transcriptional elongation. , 1999, Virology.
[22] B. Berkhout,et al. trans activation of human immunodeficiency virus type 1 is sequence specific for both the single-stranded bulge and loop of the trans-acting-responsive hairpin: a quantitative analysis , 1989, Journal of virology.
[23] G. Varani,et al. Targeting RNA with small-molecule drugs: therapeutic promise and chemical challenges. , 2001, Accounts of chemical research.
[24] T. Rana,et al. Biochemical and functional interactions between HIV-1 Tat protein and TAR RNA. , 1999, Archives of biochemistry and biophysics.
[25] J. Lakowicz. Principles of fluorescence spectroscopy , 1983 .
[26] P. Skolnick,et al. Aminoglycoside neurotoxicity involves NMDA receptor activation , 1999, Brain Research.
[27] J. Sodroski,et al. The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat , 1985, Cell.
[28] B. Berkhout,et al. Tat trans-activates the human immunodeficiency virus through a nascent RNA target , 1989, Cell.
[29] A. W. Czarnik,et al. Inhibitors of protein-RNA complexation that target the RNA: specific recognition of human immunodeficiency virus type 1 TAR RNA by small organic molecules. , 1998, Biochemistry.
[30] J. Karn,et al. Human immunodeficiency virus type-1 Tat is an integral component of the activated transcription-elongation complex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[31] R Blumenthal,et al. Quantitation of human immunodeficiency virus type 1 infection kinetics , 1993, Journal of virology.
[32] T. Rana,et al. HIV-1 TAR RNA Recognition by an Unnatural Biopolymer , 1997 .
[33] C. Wong,et al. RNA as a target for small molecules. , 2000, Current opinion in chemical biology.
[34] C. Bailly,et al. Molecular basis of HIV-1 TAR RNA specific recognition by an acridine tat-antagonist. , 1999, Bioorganic & medicinal chemistry.
[35] J. Wengel,et al. Inhibition of HIV-1 Tat-dependent trans activation by steric block chimeric 2'-O-methyl/LNA oligoribonucleotides. , 2001, Biochemistry.
[36] Ruben Abagyan,et al. Identification of ligands for RNA targets via structure-based virtual screening: HIV-1 TAR , 2000, J. Comput. Aided Mol. Des..
[37] K. Jeang,et al. Multifaceted Activities of the HIV-1 Transactivator of Transcription, Tat* , 1999, The Journal of Biological Chemistry.
[38] D. Hazuda,et al. P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. , 1997, Genes & development.
[39] T. Rana,et al. Tat-associated Kinase (P-TEFb): a Component of Transcription Preinitiation and Elongation Complexes* , 1999, The Journal of Biological Chemistry.
[40] B. Cullen,et al. Genetic analysis of the cofactor requirement for human immunodeficiency virus type 1 Tat function , 1993, Journal of virology.
[41] Zhihua Du,et al. Structure-based computational database screening, in vitro assay, and NMR assessment of compounds that target TAR RNA. , 2002, Chemistry & biology.
[42] J. Karn,et al. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[43] T. Klimkait,et al. A new class of HIV-1 Tat antagonist acting through Tat-TAR inhibition. , 1998, Biochemistry.
[44] D. P. Mack,et al. Discovery of selective, small-molecule inhibitors of RNA complexes--I. The Tat protein/TAR RNA complexes required for HIV-1 transcription. , 1997, Bioorganic & medicinal chemistry.
[45] T. Klimkait,et al. Inhibition of HIV-1 Tat-TAR interaction by diphenylfuran derivatives: effects of the terminal basic side chains. , 1999, Bioorganic & medicinal chemistry.
[46] K. Jeang,et al. Human immunodeficiency viruses regulated by alternative trans‐activators: genetic evidence for a novel non‐transcriptional function of Tat in virion infectivity. , 1994, The EMBO journal.
[47] B. Cullen. HIV-1 Auxiliary Proteins: Making Connections in a Dying Cell , 1998, Cell.
[48] M. Mathews,et al. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. , 1997, Genes & development.